BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

155 related articles for article (PubMed ID: 37306182)

  • 1. Ribociclib-induced visual hallucination in a patient with metastatic breast cancer.
    Kapagan T; Bulut N; Demirer S; Erdem GU
    J Oncol Pharm Pract; 2023 Sep; 29(6):1529-1532. PubMed ID: 37306182
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cost-Effectiveness of Ribociclib plus Letrozole Versus Palbociclib plus Letrozole and Letrozole Monotherapy in the First-Line Treatment of Postmenopausal Women with HR+/HER2- Advanced or Metastatic Breast Cancer: A U.S. Payer Perspective.
    Mistry R; May JR; Suri G; Young K; Brixner D; Oderda G; Biskupiak J; Tang D; Bhattacharyya S; Mishra D; Bhattacharyya D; Dalal AA
    J Manag Care Spec Pharm; 2018 Jun; 24(6):514-523. PubMed ID: 29799329
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Ribociclib in HR+/HER2- Advanced or Metastatic Breast Cancer Patients.
    Rascon K; Flajc G; De Angelis C; Liu X; Trivedi MV; Ekinci E
    Ann Pharmacother; 2019 May; 53(5):501-509. PubMed ID: 30522347
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Budget impact of including ribociclib in combination with letrozole on US payer formulary: first-line treatment of post-menopausal women with HR+/HER2- advanced or metastatic breast cancer.
    Mistry R; Suri G; Young K; Hettle R; May JR; Brixner D; Oderda G; Biskupiak J; Tang D; Bhattacharyya D; Bhattacharyya S; Mishra D; Dalal AA
    Curr Med Res Opin; 2018 Dec; 34(12):2143-2150. PubMed ID: 30032697
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Treatment efficacy of ribociclib or palbociclib plus letrozole in hormone receptor-positive/HER2-negative metastatic breast cancer.
    Kahraman S; Erul E; Seyyar M; Gumusay O; Bayram E; Demirel BC; Acar O; Aksoy S; Baytemur NK; Sahin E; Cabuk D; Basaran G; Paydas S; Yaren A; Guven DC; Erdogan AP; Demirci U; Yasar A; Bayoglu İV; Hizal M; Gulbagci B; Paksoy N; Davarci SE; Yilmaz F; Dogan O; Orhan SO; Kayikcioglu E; Aytac A; Keskinkilic M; Mocan EE; Unal OU; Aydin E; Yucel H; Isik D; Eren O; Uluc BO; Ozcelik M; Hacibekiroglu I; Aydiner A; Demir H; Oksuzoglu B; Cilbir E; Cubukcu E; Cetin B; Oktay E; Erol C; Okutur SK; Yildirim N; Alkan A; Selcukbiricik F; Aksoy A; Karakas Y; Ozkanli G; Duman BB; Aydin D; Dulgar O; Er MM; Teker F; Yavuzsen T; Aykan MB; Inal A; Iriagac Y; Kalkan NO; Keser M; Sakalar T; Menekse S; Kut E; Bilgin B; Karaoglanoglu M; Sunar V; Ozdemir O; Turhal NS; Karadurmus N; Yalcin B; Nahit Sendur MA
    Future Oncol; 2023 Mar; 19(10):727-736. PubMed ID: 37133230
    [No Abstract]   [Full Text] [Related]  

  • 6. Updated results from MONALEESA-2, a phase III trial of first-line ribociclib plus letrozole versus placebo plus letrozole in hormone receptor-positive, HER2-negative advanced breast cancer.
    Hortobagyi GN; Stemmer SM; Burris HA; Yap YS; Sonke GS; Paluch-Shimon S; Campone M; Petrakova K; Blackwell KL; Winer EP; Janni W; Verma S; Conte P; Arteaga CL; Cameron DA; Mondal S; Su F; Miller M; Elmeliegy M; Germa C; O'Shaughnessy J
    Ann Oncol; 2018 Jul; 29(7):1541-1547. PubMed ID: 29718092
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Safety and efficacy of ribociclib plus letrozole in patients with HR+, HER2- advanced breast cancer: Results from the Spanish sub-population of the phase 3b CompLEEment-1 trial.
    Salvador Bofill J; Moreno Anton F; Rodriguez Sanchez CA; Galve Calvo E; Hernando Melia C; Ciruelos Gil EM; Vidal M; Jiménez-Rodriguez B; De la Cruz Merino L; Martínez Jañez N; Villanueva Vazquez R; de Toro Salas R; Anton Torres A; Alvarez Lopez IM; Gavila Gregori J; Quiroga Garcia V; Vicente Rubio E; De la Haba-Rodriguez J; Gonzalez-Santiago S; Diaz Fernandez N; Barnadas Molins A; Cantos Sanchez de Ibargüen B; Delgado Mingorance JI; Bellet Ezquerra M; de Casa S; Gimeno A; Martin M
    Breast; 2022 Dec; 66():77-84. PubMed ID: 36206609
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Ribociclib as First-Line Therapy for HR-Positive, Advanced Breast Cancer.
    Hortobagyi GN; Stemmer SM; Burris HA; Yap YS; Sonke GS; Paluch-Shimon S; Campone M; Blackwell KL; André F; Winer EP; Janni W; Verma S; Conte P; Arteaga CL; Cameron DA; Petrakova K; Hart LL; Villanueva C; Chan A; Jakobsen E; Nusch A; Burdaeva O; Grischke EM; Alba E; Wist E; Marschner N; Favret AM; Yardley D; Bachelot T; Tseng LM; Blau S; Xuan F; Souami F; Miller M; Germa C; Hirawat S; O'Shaughnessy J
    N Engl J Med; 2016 Nov; 375(18):1738-1748. PubMed ID: 27717303
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Ribociclib with letrozole vs letrozole alone in elderly patients with hormone receptor-positive, HER2-negative breast cancer in the randomized MONALEESA-2 trial.
    Sonke GS; Hart LL; Campone M; Erdkamp F; Janni W; Verma S; Villanueva C; Jakobsen E; Alba E; Wist E; Favret AM; Bachelot T; Hegg R; Wheatley-Price P; Souami F; Sutradhar S; Miller M; Germa C; Burris HA
    Breast Cancer Res Treat; 2018 Feb; 167(3):659-669. PubMed ID: 29058175
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Ribociclib plus letrozole versus chemotherapy for postmenopausal women with hormone receptor-positive, HER2-negative, luminal B breast cancer (CORALLEEN): an open-label, multicentre, randomised, phase 2 trial.
    Prat A; Saura C; Pascual T; Hernando C; Muñoz M; Paré L; González Farré B; Fernández PL; Galván P; Chic N; González Farré X; Oliveira M; Gil-Gil M; Arumi M; Ferrer N; Montaño A; Izarzugaza Y; Llombart-Cussac A; Bratos R; González Santiago S; Martínez E; Hoyos S; Rojas B; Virizuela JA; Ortega V; López R; Céliz P; Ciruelos E; Villagrasa P; Gavilá J
    Lancet Oncol; 2020 Jan; 21(1):33-43. PubMed ID: 31838010
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Proton pump inhibitors may reduce the efficacy of ribociclib and palbociclib in metastatic breast cancer patients based on an observational study.
    Eser K; Önder AH; Sezer E; Çil T; İnal A; Öztürk B; Erçolak V; Duman BB; Çelik H; Köşeci T; Kesen O
    BMC Cancer; 2022 May; 22(1):516. PubMed ID: 35525929
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cyclin-dependent kinase 4/6 inhibitors for the management of advanced or metastatic breast cancer in women.
    Cersosimo RJ
    Am J Health Syst Pharm; 2019 Aug; 76(16):1183-1202. PubMed ID: 31369120
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The cyclin-dependent kinase 4/6 inhibitor palbociclib in combination with letrozole versus letrozole alone as first-line treatment of oestrogen receptor-positive, HER2-negative, advanced breast cancer (PALOMA-1/TRIO-18): a randomised phase 2 study.
    Finn RS; Crown JP; Lang I; Boer K; Bondarenko IM; Kulyk SO; Ettl J; Patel R; Pinter T; Schmidt M; Shparyk Y; Thummala AR; Voytko NL; Fowst C; Huang X; Kim ST; Randolph S; Slamon DJ
    Lancet Oncol; 2015 Jan; 16(1):25-35. PubMed ID: 25524798
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Ribociclib plus letrozole in early breast cancer: A presurgical, window-of-opportunity study.
    Curigliano G; Gómez Pardo P; Meric-Bernstam F; Conte P; Lolkema MP; Beck JT; Bardia A; Martínez García M; Penault-Llorca F; Dhuria S; Tang Z; Solovieff N; Miller M; Di Tomaso E; Hurvitz SA
    Breast; 2016 Aug; 28():191-8. PubMed ID: 27336726
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Expanded-Access Study of Palbociclib in Combination With Letrozole for Treatment of Postmenopausal Women With Hormone Receptor-Positive, HER2-Negative Advanced Breast Cancer.
    Stearns V; Brufsky AM; Verma S; Cotter MJ; Lu DR; Dequen F; Joy AA
    Clin Breast Cancer; 2018 Dec; 18(6):e1239-e1245. PubMed ID: 30172722
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Ribociclib for the first-line treatment of advanced hormone receptor-positive breast cancer: a review of subgroup analyses from the MONALEESA-2 trial.
    Hortobagyi GN
    Breast Cancer Res; 2018 Oct; 20(1):123. PubMed ID: 30340505
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Ribociclib induced acute kidney injury: A case report.
    Gulturk I; Yilmaz M; Ozmen A; Tacar SY; Erdal GS; Tural D
    J Oncol Pharm Pract; 2021 Dec; 27(8):2023-2026. PubMed ID: 33847193
    [TBL] [Abstract][Full Text] [Related]  

  • 18. PRECYCLE: multicenter, randomized phase IV intergroup trial to evaluate the impact of eHealth-based patient-reported outcome (PRO) assessment on quality of life in patients with hormone receptor positive, HER2 negative locally advanced or metastatic breast cancer treated with palbociclib and an aromatase inhibitor or palbociclib and fulvestrant.
    Degenhardt T; Fasching PA; Lüftner D; Müller V; Thomssen C; Schem C; Witzel I; Decker T; Tesch H; Kümmel S; Uleer C; Wuerstlein R; Hoffmann O; Warm M; Marschner N; Schinköthe T; Kates RE; Schumacher J; Otremba B; Zaiss M; Harbeck N; Schmidt M;
    Trials; 2023 May; 24(1):338. PubMed ID: 37198674
    [TBL] [Abstract][Full Text] [Related]  

  • 19. FDA Approval: Ribociclib for the Treatment of Postmenopausal Women with Hormone Receptor-Positive, HER2-Negative Advanced or Metastatic Breast Cancer.
    Shah A; Bloomquist E; Tang S; Fu W; Bi Y; Liu Q; Yu J; Zhao P; Palmby TR; Goldberg KB; Chang CJG; Patel P; Alebachew E; Tilley A; Pierce WF; Ibrahim A; Blumenthal GM; Sridhara R; Beaver JA; Pazdur R
    Clin Cancer Res; 2018 Jul; 24(13):2999-3004. PubMed ID: 29437768
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Toxic hepatitis in metastatic breast cancer patient using ribociclib and denosumab.
    Bayram D; Aktürk Esen S; Uçar G; Köş FT
    J Oncol Pharm Pract; 2023 Sep; 29(6):1494-1497. PubMed ID: 37170613
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.